The Australian reports the successful conclusion of Race’s lead drug AML study
The Australian reports the conclusion of Race’s Phase 1b/2 investigator-sponsored trial of RC110 bisantrene in relapsed or refractory acute myeloid leukaemia patients, conducted at the Chaim Sheba Medical Centre in Israel and led by Professor Arnon Nagler.
The results show that 40% of patients with highly advanced disease showing a response to bisantrene.
Read the full article here.